Cover Image
市場調查報告書

乾燥症候群(修格蘭氏症候群) : 開發平台分析

Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 350596
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
乾燥症候群(修格蘭氏症候群) : 開發平台分析 Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 104 Pages
簡介

乾燥症候群(修格蘭氏症候群)是自體免疫疾病,會引起身體分泌腺及其他組織的發炎。症狀有皮疹和乾性皮膚,陰道乾燥,持續性乾咳,慢性疲勞,乾眼症,乾唇,關節痛,腫,僵硬等。原因有老齡化,性別,風濕性疾病等。

本報告提供乾燥症候群(修格蘭氏症候群)的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞和發表的企業和研究機關正在開發之治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

乾燥症候群(修格蘭氏症候群) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/研究機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關研究中的產品

治療藥的開發企業

  • Akari Therapeutics, Plc
  • Amgen Inc.
  • Ampio Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline Plc
  • MedImmune, LLC
  • Novartis AG
  • Redx Pharma Plc
  • Toleranzia AB
  • UCB S.A.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9440IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 4, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sicca Syndrome (Sjogren) - Overview
    • Sicca Syndrome (Sjogren) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Sicca Syndrome (Sjogren) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development
    • Akari Therapeutics Plc
    • Amgen Inc
    • Atlantic Bio Sci LLC
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Galapagos NV
    • Gilead Sciences Inc
    • GlaxoSmithKline Plc
    • Immunwork Inc
    • MedImmune LLC
    • Novartis AG
    • Redx Pharma Plc
    • Samjin Pharmaceutical Co Ltd
    • UCB SA
    • XTL Biopharmaceuticals Ltd
  • Sicca Syndrome (Sjogren) - Drug Profiles
    • abatacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABS-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-557 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab + rituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986142 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CFZ-533 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Coversin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edratide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-9876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2618960 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMSO-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leniolisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lulizumab pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3090106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-4920 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-7734 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7625 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSLV-132 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SA-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seletalisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TE-2324 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tirabrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAY-736 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sicca Syndrome (Sjogren) - Dormant Projects
  • Sicca Syndrome (Sjogren) - Discontinued Products
  • Sicca Syndrome (Sjogren) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 05, 2017: XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome
      • Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib
      • Feb 13, 2017: XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome
      • Jan 05, 2017: XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjogren's Syndrome
      • Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Sicca Syndrome (Sjogren), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics Plc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Galapagos NV, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Gilead Sciences Inc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Immunwork Inc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by MedImmune LLC, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by UCB SA, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by XTL Biopharmaceuticals Ltd, H1 2017
  • Sicca Syndrome (Sjogren) - Dormant Projects, H1 2017
  • Sicca Syndrome (Sjogren) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Sicca Syndrome (Sjogren), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top